Pfizer Inlyta’s Toxicity Data Help Clinch Unanimous ODAC Support
This article was originally published in The Pink Sheet Daily
Executive Summary
Axitinib as treatment for advanced renal cell carcinoma has a different toxicity profile from Bayer HealthCare's Nexavar (sorafenib), which member of the Oncologic Drugs Advisory Committee found important, even as FDA urged the panel not to focus on compartive safety and effecacy.